© Reuters.
WASHINGTON (Reuters) – COVID-19 vaccines that specifically target the Omicron and other variants are under development, Pfizer Inc (NYSE 🙂 ‘s chief executive said on Wednesday, adding that the company will be able to quickly adapt shots as the novel coronavirus mutates.
While the ultimate approval decisions rest with US regulatos, “we are ready for that,” the drugmaker’s CEO Albert Bourla told MSNBC in an interview, noting that the Food and Drug Administration is convening a meeting later this month.